GlobeNewswire

In-Memory Computing Summit Europe Announces Full Breakout Session Schedule

Dela

Register by April 29th to Receive a 30 Percent Discount

 

FOSTER CITY, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing platform solutions based on Apache® Ignite(TM), today released the full breakout session schedule for the second annual In-Memory Computing Summit® Europe, the premier conference for individuals from Europe and Asia that are currently using or exploring using in-memory computing. Conference breakout sessions are in five tracks: Tales from the Trenches, New Capabilities, Architecture, Streaming Data, and Hardware. Speakers include representatives from companies such as Oracle, Intel, NEC Corporation of America, GridGain Systems, Hazelcast, iguazio, Neeve Research, ScaleOut Software, Software AG, Bouquet.ai, and VoltDB. The IMC Summit Europe will take place at the Park Plaza Victoria London, June 25-26, 2018. Attendees can receive a 30 percent Super Saver discount off the full price registration fee by purchasing their ticket by April 29, 2018.

The In-Memory Computing Summit Europe 2018 is the only conference focusing on the full range of in-memory computing-related technologies and solutions. Attendees will learn about the role of in-memory computing in enterprise use cases such as digital transformation and omnichannel customer experience initiatives. The conference is attended by technical decision makers, business decision makers, architects, CTOs, developers and more who make or influence purchasing decisions about in-memory computing, Big Data, Fast Data, IoT and HPC solutions.

Conference Schedule
This year's European conference includes 30 engaging and informative breakout sessions on a wide range of topics, including the following and more:

  • When One Minute Can Cost You a Million: Predicting Share Prices in Real-Time with Apache Spark and Apache Ignite - Manuel Mourato, Big Data Engineer, Nomad Tech
  • Intel Memory Drive Technology (IMDT) - Ravikanth Durgavajhala, SSD Solutions Architect, Intel Corporation
  • TimesTen Scaleout: Functionality, Architecture and Performance Tuning - Chris Jenkins, Senior Director, In-Memory Technology, Oracle
  • When Scientific High Performance Computing (HPC) Meets Big Data Tools - Tsvi Lev, General Manager of the NEC Israeli Research Center, NEC Corporation of America
  • Things You Learn as You Massively Scale - David Rolfe, Director of Solutions Engineering, VoltDB Inc.
  • How to Build an Event-Driven, Dynamically Re-Configurable Micro-Services Platform - Sven Beauprez, Lead Architect, The Glue
  • Integrating Data-Parallel Analytics into Stream-Processing Using an In-Memory Data Grid - William Bain, CEO, ScaleOut Software, Inc.
  • Designing Multi-Cluster Applications - Lucas Beeler, Senior Consultant, GridGain Systems
  •  "Hybrid Transactional Analytical Processing (HTAP)" the Key to Intelligent Systems - Kevin Goldstein, Senior Principal Architect, Neeve Research
  • Apache Ignite as MPP Accelerator - Alexander Ermakov, Chief Technology Officer, Arenadata
  • Real-Time with Artificial Intelligence: The Convergence of Big Data and Artificial Intelligence - Colin MacNaughton, Head of Engineering, Neeve Research
  • Fast and Robust Complex Event Processing Using Apache Ignite - Viktor Khodiakov, CEO, Gridfore
  • Speed-of-Light Faceted Search via Oracle In-Memory Option - Alexander Tokarev, DB Tech Lead, DataArt
  • Ways to Recover In-Memory Data on a Disaster - Alparslan Avci, Solutions Architect, Hazelcast
  • Distributed Database DevOps Dilemmas? Kubernetes to the Rescue! - Akmal Chaudhri, Technical Evangelist, GridGain Systems
  • Pushing Enterprise Software to the Next Level - Self-Contained Web Applications on In-Memory Platforms - Michal Nosek, Software Engineer, Tech Sales, Starcounter AB

Super Saver Registration Discounts
Attendees can receive a 30 percent discount by registering early. The Super Saver General Admission rate of £375 ends on April 29, 2018. Register via the conference website, or email attendance and registration questions to info@imcsummit.org.

Sponsorships 
By sponsoring the In-Memory Computing Summit Europe, organizations gain a unique opportunity to enhance their visibility and reputation as leaders in in-memory computing products and services. They can interact with key in-memory computing business and technical decision makers, connect with technology purchasers and influencers, and help shape the future of Fast Data. A limited number of Platinum, Gold and Silver sponsorship packages are currently available. Some of the current sponsors include:

  • Platinum Sponsors - GridGain Systems
  • Gold Sponsors - ScaleOut Software
  • Association Sponsors - Storage Networking Industry Association (SNIA)
  • Media Sponsors - Data Centre Solutions, Digitalisation World, Enterprise Times, IT for CEOs and CFOs, IT Pro

About the In-Memory Computing Summit®
The In-Memory Computing Summits in Europe and North America are the only industry-wide events tailored to in-memory computing-related technologies and solutions. They are the perfect opportunity to connect with technical IT decision makers, IT implementers, and developers who make or influence purchasing decisions in the areas of in-memory computing, Big Data, Fast Data, IoT and HPC. Attendees include CEOs, CIOs, CTOs, VPs, IT directors, IT managers, data scientists, senior engineers, senior developers, architects and more. The Summits are unique forums for networking, education and the exchange of ideas - ideas that power the new world and future of Fast Data. For more information, visit https://imcsummit.org and follow the event on Twitter @IMCSummit.

About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite(TM). GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes Barclays, ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. GridGain delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, continuous learning and HTAP. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain and the In-Memory Computing Summit are trademarks or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite, Ignite, Apache Spark, and Spark, are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GridGain Systems via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum